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Objectives. Prognosis of elderly patients with acute myeloid leukemia (AML) remains dismal. To 
explore the potential of immunotherapy for improving the clinical outcome of these patients, we 
performed a phase I clinical trial of dendritic cell (DC)-based immunotherapy for elderly patients with 
AML. 
Materials and Methods. Autologus monocytes were obtained after reducing tumor burden by 
chemotherapy. Immature DCs induced with granulocyte-macrophage colony-stimulating factor and 
interleukin-4 were pulsed with autologous apoptotic leukemic cells as antigens. DCs were 
administered intradermally to 4 patients 5 times at 2-week intervals. To facilitate DC migration to 
lymph nodes, injection sites were pretreated with killed Streptococcus pyogenes OK-432 1 day before. 
DCs were co-injected with OK-432 to induce maturation and IL-12 production in vivo. 
Results. Anti-leukemic responses were observed by an interferon-γ enzyme-linked immunospot assay 
or a tetramer assay in 2 of the 4 patients. In an HLA-A*2402-positive patient, induction of CD8+ T cell 
responses to WT1- and hTERT-derived peptides were observed, indicating cross-priming in vivo. The 2 
patients with anti-leukemic immunity showed longer periods of disease stabilization than the other 2 
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patients. 
Conclusions. This study demonstrates the immunogenicity of autologous DCs that cross-present 








The management of elderly patients with acute myeloid leukemia (AML) remains a challenge 
because of a high rate of therapy-related mortality and chemotherapy resistance [1]. Antigen-specific 
immunotherapy, which is less toxic and kills leukemic cells through different mechanisms than 
chemotherapy, has the potential capacity to improve the clinical outcome of these patients. Recent 
identification of several leukemia-associated antigens prompted us to develop immunotherapy for 
elderly patients with AML [2]. 
Active immunization by peptide vaccines can induce anti-leukemic immunity and clinical 
responses in AML [3-6]. Clinical trials of dendritic cell (DC)-based immunotherapy for AML have also 
been reported [7-12]. However, the trial using leukemic cell-derived DCs (LCDCs) showed that the 
generation of LCDCs was feasible only in a limited number of patients, and even in vaccinated patients, 
the treatment could not induce clinical responses [9]. This may be due to lower immunostimulatory 
activity of LCDCs than monocyte-derived DCs (MoDCs) [13]. Recently, the efficient generation of 
MoDCs from patients with AML has been demonstrated in vitro [14], providing a rationale for the use 
of MoDCs in immunotherapy for AML. 
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There are several parameters to enhance the immunogenicity of MoDC vaccines. (i) Whereas 
monocytes are cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
interleukin (IL)-4 conventionally for 5 to 7 days to induce DCs, a shorter period of culture is sufficient 
to induce equivalently potent DCs [15]. (ii) Among DC maturation-inducing factors, microbial 
components that trigger the production of IL-12 are beneficial to induce effective adaptive immunity 
[16]. (iii) An extended period of stimulation with microbial components results in DC exhaustion in 
which DCs lose the capacity to produce IL-12 [17]. Thus, a short-term stimulation may generate 
optimal DCs that retain IL-12 production. (iv) Inflammation in the skin before DC injection facilitates 
the DC migration to draining lymph nodes, leading to a stronger immune response [18-19]. (v) Using 
apoptotic whole tumor cells as antigens may be instrumental in inducing multivalent immune 
responses [20]. 
We performed in vitro assays to optimize these parameters. Based on the results of these assays, 
we conducted a phase I clinical trial of immunotherapy for elderly patients with AML at the second or 
later remission setting, using DCs loaded with autologous apoptotic leukemic cells. The treatment was 
well tolerated and safe, and induced anti-leukemic immunity in 2 of 4 patients, which was associated 
with transient disease stabilization. Importantly, in one patient, cross-priming of leukemia 
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antigen-specific CD8+ T cells in vivo was explicitly demonstrated. This study indicates the safety and 
immunogenicity of immunotherapy using MoDCs that cross-present leukemic cell antigens in elderly 
patients with AML.  
 
Materials and methods 
 
Generation, maturation and cryopreservation of DCs for in vitro assays 
Peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers by density 
gradient centrifugation using Lympholyte H (Cedarlane, Ontario, Canada). Monocytes were purified 
using anti-CD14-conjugated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany), or enriched 
by plastic adherence by incubating PBMCs at 37 °C for 2 hours and removing non-adherent cells by 
pipetting. Monocytes were cultured with 800 IU/mL GM-CSF (Primmune, Kobe, Japan) and 500 
IU/mL IL-4 (Primmune) in CellGro® DC medium (CellGenix Technologie Transfer, Freiburg, 
Germany) for 3 days (3d-DCs) or 6 days (6d-DCs). In some experiments, 3d-DCs were frozen in CP-1 
freezing medium (Kyokuto Pharmaceutical Industrial, Tokyo, Japan). CP-1 contains 12% 
hydroxymethyl starch and 10% dimethylsulfoxide in normal saline and was mixed with 8% human 
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serum albumin before use. DCs were matured with 0.1 KE/mL OK-432 (Picibanil®; Chugai 
Pharmaceuticals, Tokyo, Japan), a penicillin-killed and lyophilized preparation of a low-virulence 
strain (Su) of Streptococcus pyogenes (group A) [21]. 
 
In vitro analysis of DC functions 
Flow cytometric analysis, measurement of IL-12p70 production, T cell-stimulatory capacity of DCs for 
allogeneic naive CD4+ T cells, and the cytokine profile of CD4+ T cells primed with DCs were 
analyzed as described previously [15, 22]. 
 
Uptake of apoptotic cells by DCs and the cross-presenting capacity of DCs 
Efficiency of uptake of apoptotic cells by DCs was assessed as described previously [23], using 
myeloid leukemia cell lines K562, OUN-1 [24] (Dr. Yasukawa, Ehime University, Japan) and a T-cell 
leukemia cell line MT2 that were killed by 120 Gy γ-irradiation and 48-hour serum-free culture in 
RPMI1640 (Wako Pure Chemical Industries, Osaka, Japan). To examine the cross-presenting capacity 
of DCs, HLA-A*2402-positive, immature 3d-DCs were pulsed with HLA-A*2402-negative, 
Epstein-Barr virus-transformed lymphoblastoid cell lines (LCLs) that were killed as described above. 
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DCs were matured with OK-432 (0.1 KE/mL) and prostaglandin E2 (1 μg/mL) (MP Biomedicals, 
Solon, OH) for 6 hours, and co-cultured with autologous T cells at a DC:T cell ratio of 1:10. IL-2 (50 
IU/mL; Teceleukin®; Shionogi & Co., Ltd., Osaka, Japan) was added on the next day. For a positive 
control, DCs pulsed with HLA-A*2402-restricted EBNA3B peptide (TYSAGIVQI; KURABO 
Industries, Osaka, Japan) were used. Expansion of EBNA3A- and EBNA3B-specific CD8+ T cells 
were evaluated by HLA tetramer staining [25]. 
 
Clinical trial protocol 
The protocol was approved by the Ethics Committee, Graduate School and Faculty of Medicine, 
Kyoto University. Each patient gave written informed consent in accordance with the Declaration of 
Helsinki. The primary and secondary objectives were the assessment of safety, and immunological and 
clinical responses, respectively. 
Autologous leukemic cells were harvested before induction chemotherapy. Patients were 
required to be between 16 and 79 years of age, and have a diagnosis of AML by the World Health 
Organization criteria [26-27]. Patients were excluded if they had another concurrent malignancy, an 
active autoimmune disease, positivity for blood-borne infectious agents, or a history of penicillin 
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allergy (because OK-432 contains penicillin). Patients were enrolled if 5 x 107 or more leukemic cells 
were harvested. Thereafter, patients were treated with chemotherapy. More than 4 weeks after the last 
chemotherapy, patients proceeded to the DC vaccination if leukemic cells in bone marrow (BM) were 
less than 20%. In addition, to assess the clinical efficacy of DC vaccination, the presence of an 
evaluable lesion in BM, which was defined as 0.1% or more of leukemic cells by flow cytometry was 
required. Furthermore, patients should have an Eastern Cooperative Oncology Group performance 
status of 0 to 2, and adequate vital organ functions. Patients were excluded if they had eligibility for 
hematopoietic stem cell transplantation or an uncontrollable infection. Concomitant chemotherapy and 
radiotherapy were prohibited. 
 
DC vaccine generation 
DC vaccines were generated from autologous monocytes under current good manufacturing 
practice conditions. Autologous leukemic cells to be used as antigens were obtained as mononuclear 
cells (MNCs) by density gradient centrifugation over Ficoll-Hypaque (GE Healthcare, 
Buckinghamshire, UK) from BM and/or peripheral blood (PB) samples. MNCs were frozen in CP-1 
freezing medium and stored at -150 °C. Before added to DCs, MNCs were killed by 120 Gy 
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γ-irradiation and 48-h serum starvation. Killing of MNCs was confirmed by the percentage of Annexin 
V-positive cells being 90% or more by flow cytometry, and reduced uptake of [3H]-thymidine to the 
baseline level. 
Apheresis products, which were obtained with COBE® Spectra™ (Caridian BCT, Lakewood, 
CO) from 10 liters of blood, were processed by elutriation using Elutra® (Caridian BCT) to enrich 
monocytes. At the time of apheresis, no leukemic cells were observed in the PB of the patients, as 
assessed by a routine clinical laboratory test Monocytes were cultured with 800 U/mL GM-CSF and 
500 U/mL IL-4 in CellGro DC medium in gas-permeable plastic bags (VueLife™ 118; CellGenix 
Technologie Transfer) at 37 °C, 5% CO2 to generate immature DCs. After 48 hours, DCs were pulsed 
with autologous apoptotic leukemic cells and 2 μg/ml keyhole-limpet hemocyanin (KLH; biosyn 
Corporation, Carlsbad, CA). The endotoxin level in the KLH preparation examined by the supplier was 
<0.1 I.U./mg. After additional 24 hours, DCs were frozen as immature DCs in CP-1 freezing medium 
and stored at -150 °C. 
 
Administration of the DC vaccine 
A total of 1 x 107 DCs were intradermally injected at four sites in bilateral arms and thighs. 
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Twenty-four hours before the DC administration, the injection sites were pretreated by 0.2 KE/site 
OK-432. At the time of DC administration, DCs were thawed and mixed with 1 KE OK-432. Then, the 
mixture of DCs and OK-432 was injected. The DC administration was repeated at 2-week intervals for 
5 administrations. 
 
Monitoring of immunological and clinical responses 
Antigen-specific immune responses were assessed at indicated time points. Immune responses to 
KLH and autologous leukemic cells were tested by skin delayed-type hypersensitivity (DTH) tests and 
IFN-γ enzyme-linked immunospot (ELISPOT) assays. In addition, in a HLA-A*2402 positive patient, 
immune responses to HLA-A*2402-restricted peptides derived from leukemia-associated antigens 
were examined by IFN-γ ELISPOT assay and HLA tetramer staining. The peptides used in the assays 
were the natural WT1235-243 peptide (CMTWNQMNL) [24], the modified WT1235-243 peptide 
(CYTWNQMNL) [28], the human telomerase reverse transcriptase (hTERT)461-469 peptide 
(VYGFVRACL) [29], and the lower matrix 65-kd phosphoprotein (pp65) of CMV (amino acids 
328-336; QYDPVAALF) [29]. All peptides were purchased from Multiple Peptide Systems (San Diego, 
CA). Both PBMCs and BM mononuclear cells (BMMCs) were subjected to assays before and after 
 12 
1-week in vitro stimulation with antigen- or peptide-pulsed DCs in the presence of 15 U/mL IL-2 
(Teceleukin®). To evaluate clinical responses, percentages of leukemic cells in BM were monitored by 
morphology and flow cytometry at indicated time points. 
 
Skin DTH test 
Four x 105 antigen-pulsed DCs were intradermally injected in the forearm. Sizes of induration 
and erythema were measured 48 hours later. Erythema that was 1.5-fold or larger in a diameter than the 
antigen-unpulsed control were considered positive. 
 
IFN-γ ELISPOT assay 
IFN-γ ELISPOT assays (Mabtech, Nacka Strand, Sweden) were performed using antigen-pulsed 
DCs and peptide-pulsed C1R-A*2402 (Dr. Masafumi Takiguchi, Kumamoto University, Kumamoto, 
Japan). Stimulator cells were plated at 2 x 104 cells/well. As responder cells, fresh and in vitro 
stimulated MNCs from PB and BM were plated with fresh MNCs at 1-2 x 105 cells/well and in vitro 
stimulated MNCs at 1-2 x 104 cells/well. After overnight incubation, spots were developed using 
3-Amino-9-ethylcarbazole (Sigma Chemical, St. Louis, MO) and counted by KS ELISPOT compact 
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(Carl Zeiss MicroImaging, Tokyo, Japan). Numbers of specific spot-forming cells were calculated by 
subtracting the number of spots with unpulsed DCs from the number of spots with antigen-pulsed DCs. 
 
HLA tetramer staining 
Natural WT1235-243 peptide/HLA-A*2402 tetramer was purchased from Medical & Biological 
Laboratories (Nagoya, Japan). Modified WT1235-243 peptide/HLA-A*2402 tetramer and a peptide 
derived from the HIV envelope (env) protein/HLA-A*2402 tetramer were produced as described 
previously [29]. Fresh and in vitro stimulated MNCs were stained with a tetramer and 
FITC-conjugated anti-CD8 mAb (BD Biosciences) and analyzed by flow cytometery (FACSCalibur™; 




In vitro assays to optimize the generation of DCs 
To optimize the generation of DCs, we performed in vitro functional assays. We first compared 
DCs differentiated from monocytes in the presence of GM-CSF and IL-4 for 3 days (3d-DCs) with 
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6-day differentiated DCs (6d-DCs) conventionally used in clinical trials. After 24-hour exposure to 
OK-432, both 3d-DCs and 6d-DCs showed similar levels of surface molecule expressions, IL-12p70 
production, and T cell stimulatory capacity for allogeneic naive CD4+ T cells (Supplementary Fig. S1), 
indicating that 3d-DCs have comparable functions with 6d-DCs. Next, we examined the capacity of 
3d-DCs to cross-present apoptotic cell-associated antigens. At the DC:apoptotic cell ratio of 1:1, 11 to 
33% of immature 3d-DCs incorporated apoptotic leukemia cell lines (Fig. 1A). Moreover, 
HLA-A*2402-positive DCs pulsed with killed LCLs from an HLA-A*2402-negative donor induced 
expansion of CD8+ T cells specific for the HLA-A*2402-restricted epitopes of EBNA3A and EBNA3B 
(Fig. 1B), indicating the capacity of DCs to cross-present apoptotic cell-derived antigens. 
An extended period of exposure of DCs to lipopolysaccharide (LPS) leads to DC exhaustion 
[17], as indicated by loss of the IL-12-producing capacity by DCs. To examine whether OK-432 
induces DC exhaustion, we analyzed the maturation kinetics of OK-432-stimulated 3d-DCs. 
Up-regulation of the surface molecules (Fig. 2A) and IL-12p70 production (Fig. 2B) became evident 4 
and 8 hours after OK-432 stimulation, respectively. Maximal levels of surface molecule expressions 
and IL-12p70 production were observed at 48 hours. Next, we examined how many hours of exposure 
to OK-432 is sufficient to elicit a maturation signal to DCs, using 3d-DCs that were cultured for a total 
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of 48 hours with different durations of exposure to OK-432 at the start of culture. As short as 2-hour 
exposure up-regulated CD83 and CD86 (Fig. 2C) and induced IL-12p70 production (Fig. 2D) during 
the subsequent 46-hour culture without OK-432. Although at the time of 8-hour exposure, the 
induction of CD83, CD86 (Fig. 2A) and IL-12p70 (Fig. 2B) was low, 8-hour exposure was sufficient to 
induce maximal levels of CD83 and CD86 expression (Fig. 2C) and IL-12p70 production (Fig. 2D). 
Notably, although initial 24-hour exposure to OK-432 induced the maximal levels of CD83 and CD86 
expression (Fig. 2C), DCs did not produce a detectable level of IL-12p70 during the last 24-hour 
culture (Fig. 2D). These data indicate that like LPS [17], OK-432-induced IL-12p70 production was 
limited within the first 24 hours, and most active between 8 and 24 hours after OK-432 stimulation. 
The functional significance of ongoing IL-12p70 production by DCs in priming naive CD4+ T cells 
was supported by the data that 3d-DCs matured with OK-432 for 6 hours showed a superior capacity to 
induce IFN-γ-producing T cells to those matured for 24 hours (Fig. 2E). Thus, extended stimulation 
with OK-432 induces DC exhaustion. To avoid it, we decided to administer immature DCs together 
with OK-432 to patients and to induce DC maturation in vivo. 
It is convenient to prepare a large number of DCs from a single batch of apheresis and freeze 
them in aliquots. We assessed the effect of cryopreservation on DCs. Whereas cryopreserved immature 
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3d-DCs showed somewhat higher percentages of dead cells after 24h-culture with or without OK-432, 
and tended to produce a lower amount of IL-12p70 upon OK-432 stimulation as compared with 
non-cryopreserved DCs (Supplementary Fig. S2A, C), similar levels of CD83 and CD86 expression 
was induced by OK-432 in both DCs (Supplementary Fig. S2B). Thus, although cryopreservation of 
immature DCs impaired their functions to some extent, cryopreserved DCs largely retained the 
viability and expressions of immunostimulatory molecules. Considering the practical convenience to 
prepare a stock of DCs at one time, we decided to freeze DCs as immature DCs. Taken together, these 
data demonstrate that DCs generated in the present study are capable of inducing CD8+ T cell 
responses to apoptotic cell-derived antigens, and that immature DCs can be cryopreserved without 
critical loss of functions. 
 
Patients, feasibility and safety 
Thirteen patients were recruited to the study for the leukemic cell harvest at the onset of AML. 
After chemotherapy, 4 patients were eligible for the DC vaccination (Table 1). In these patients, more 
than 5 x 107 DCs for 5 vaccinations could be generated from a single apheresis. Autologous apoptotic 
leukemic cells were added to DCs as antigens at leukemic cell:DC ratios of 1:3.3 to 1:6.5, depending 
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on the numbers of collected leukemic cells (Supplementary Table 1). Status of PB and BM at the time 
of apheresis are shown in Supplementary Table 1. Representative data of surface molecule expressions 
on DCs are shown in Supplementary Fig. S3. 
All the patients completed the 5 vaccinations safely (Table 1). In all the patients, grade 1-2 fever 
and grade 2 skin reactions at the injection sites were observed. The fever was resolved within 2 days 
after vaccination, and most likely related to the administration of OK-432. The skin reactions at the 
injection sites were transient and characterized by erythema, pruritus, and tenderness. No significant 
toxicities to vital organs or signs of autoimmunity were observed. 
 
Induction of antigen-specific immune responses to KLH and leukemic cells 
Induction of an immune response to KLH was detected by skin DTH tests and/or IFN-γ 
ELISPOT assays in 3 patients except Patient #4 (Table 1 and data not shown). Two patients (Patients 
#2 and #3) showed induction of immune responses to leukemia-associated antigens. In Patient #2, who 
was HLA-A*2402-negative, IFN-γ ELISPOT assays using autologous leukemic cell-pulsed DCs 
revealed the induction of anti-leukemic immunity in PBMCs and BMMCs without in vitro stimulation 
after the 4th vaccination (Figs. 3A). The anti-leukemic immune response was still detected 1 month 
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after the 5th vaccination in in vitro stimulated PBMCs and BMMCs (Fig. 3B), but was no longer 
detected without in vitro stimulation (Fig. 3A). We could not test anti-leukemic immunity at 
subsequent time points in this patient because the patient developed leukocytopenia probably owing to 
progression of MDS. 
In Patient #3, who was HLA-A*2402-positive, HLA-A*2402-restricted peptides from WT1 and 
hTERT were used in immunological monitoring. CMVpp65328-336 peptide was used as a positive 
control in ELISPOT assays (Fig. 4B). No responses to the leukemia-associated antigens were observed 
until the 4th vaccination. However, 2 months after the 5th vaccination, positive responses to the 
modified WT1235-243 and the hTERT461-469 peptides were detected in in vitro stimulated PBMCs by 
HLA tetramer staining (Fig. 4A) and an IFN-γ ELISPOT assay (Fig. 4B), respectively. The PBMCs 
binding to the modified WT1235-243 peptide/HLA-A*2402 tetramer also bound to the natural WT1235-243 
peptide/HLA-A*2402 tetramer (Fig. 4A), indicating that these cells were capable of recognizing the 
natural WT1 peptide presented on leukemic cells. These responses were short-lived and almost 
completely disappeared 3 months after the 5th vaccination. No responses were detected in PBMCs or 
BMMCs without in vitro stimulation (data not shown). Thus, the vaccinations induced HLA class 
I-restricted, anti-leukemic immunity, indicating that the DCs cross-presented leukemia-associated 
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antigens in vivo. In addition, in Patient #2, leukemic cell-reactive T cells were detected in BM (Fig. 3), 
the main tumor site in leukemia. 
 
Clinical outcome 
The 2 patients with anti-leukemic immunity had longer periods of disease stabilization than the 
other 2 patients without anti-leukemic immunity (Fig. 5A). Notably, in Patient #3, the percentages of 
leukemic cells in BM dropped from 11% to 5.2% during the second month after the 5th vaccination, 
when a positive anti-leukemic immunity was observed (Fig. 5B). Thus, these observations suggest that 
induction of anti-leukemic immunity was associated with extended the periods of disease stabilization 




Novel therapies with less toxicity are necessary for intractable AML in elderly patients. In this 
study, we conducted a phase I clinical trial of immunotherapy for such patients using DCs pulsed with 
autologous apoptotic leukemic cells. Induction of anti-leukemic immunity was observed in 2 of 4 
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vaccinated patients. This is the first study that demonstrates cross-priming of CD8+ T cells by DCs 
pulsed with apoptotic leukemic cells in vivo in humans, thus providing a proof of principle of this 
approach. The limited number of the patients prevented us from drawing any definitive conclusion 
regarding clinical efficacy from the present trial. However, longer periods of disease stabilization 
observed in the 2 patients with anti-leukemic immunity compared to the other 2 patients without 
anti-leukemic immunity implied that induction of anti-leukemic immunity might have impacted on the 
clinical course of these patients. 
There are several features in the method of DC vaccination in this trial: (i) short-term 3-day 
culture to generate DCs in an attempt to reduce labor, cost, and time, (ii) use of whole leukemic cells 
as antigens to induce multivalent immune responses, (iii) use of the microbial adjuvant OK-432 as a 
maturation-inducing factor to generate Th1-inducing DCs, (iv) in vivo maturation of DCs to avoid DC 
exhaustion by extended stimulation in vitro with OK-432, and (v) prior induction of inflammation at 
the injection sites to facilitate DC migration to draining lymph nodes. 
We used autologous apoptotic leukemic cells as antigens, because several studies have shown 
that apoptotic cells are more efficiently cross-presented by DCs to CD8+ T cells than soluble antigens 
such as tumor lysate [30-33]. Furthermore, MoDCs has been shown to cross-present apoptotic 
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leukemic cells to CD8+ T cells in vitro [34]. Apoptotic cells as antigens also have advantages over 
peptides, in that the DCs have the ability to process multiple antigens from the apoptotic cells and 
present those antigens on their own HLA molecules. In this study, we clearly showed that MoDCs 
cross-presented leukemia-associated antigens, WT1 and hTERT from apoptotic leukemic cells. 
Furthermore, T cells reactive to leukemic cells were detected in BM. 
A murine study has shown that DC maturation not by inflammatory cytokines but by 
pathogen-derived components is crucial for DCs to acquire the capacity to differentiate naive CD4+ T 
cells into effector T cells [16]. We used OK-432, a preparation of killed Streptococcus pyogenes [21], 
which strongly triggers DC maturation through Toll-like receptor (TLR) 4 [35-38]. We showed that, 
like LPS [17], longer stimulation with OK-432 induces DC exhaustion, resulting in the reduced 
capacity of DCs to induce Th1 responses. Several preclinical studies have shown that DCs briefly 
exposed to TLR ligands are better inducers of Th1-type and cytotoxic T cell responses [17, 39-40]. 
Moreover, a clinical trial suggests superiority of briefly matured DCs in pediatric patients with cancer 
[41]. In this trial, we administered immature DCs together with OK-432 to avoid DC exhaustion before 
administration. The induction of IFN-γ detected by the ELISPOT assay implied IL-12 production by 
DCs in vivo. 
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Only a small proportion of intradermally administered DCs reach draining lymph nodes [42-43]. 
In a mouse model, pretreatment of administration sites with inflammatory cytokines enhance DC 
migration to regional lymph nodes [18]. Based on this finding, we pretreated administration sites with 
a low dose of OK-432. Because of unavailability of a cell processing facility for cells labeled with 
indium-111 oxyquinoline [42-43], we could not evaluate the efficiency of DC migration to lymph 
nodes. Whether this administration procedure is superior to others should be evaluated in future 
studies. 
In this study, multiple vaccinations were required to elicit anti-leukemic immunity, which 
rapidly declined after the cessation of vaccination. Maintenance of anti-leukemic immunity might lead 
to improvement of clinical efficacy, and might be fulfilled by increasing the number of vaccination, 
which was, however, impossible in this study because of the limited availability of autologous 
leukemic cells. Thus, if a peptide is available for the induced anti-leukemic CD8+ T cell response, 
peptide vaccination may be added following DC vaccination. Furthermore, blockade of 
immunosuppressive mechanisms may be combined. 
In conclusion, we demonstrated the feasibility, safety and immunogenicity of DC-based 
immunotherapy for elderly patients with AML. Cross-priming of CD8+ T cells by DCs pulsed with 
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autologous apoptotic leukemic cells was provoked in vivo. The results were promising, yet further 
intensification of vaccine potency is clearly required. This novel therapeutic approach may lead to 
improvement of clinical outcomes of elderly patients with AML, which has been difficult to be 
achieved by other therapeutic approaches. 
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Figure 1 3d-DCs incorporate apoptotic cells and cross-present cell-associated antigens. (A) Uptake of 
apoptotic cells by 3d-DCs. Apoptotic K562, OUN-1 and MT2 were labeled with 7-AAD (20 μg/mL), 
and co-cultured with immature 3d-DCs at a DC:apoptotic cell ratio of 1:1. After 4 hours of incubation 
at 4°C or 37°C, cells were stained with FITC-conjugated anti-CD11c mAb and analyzed by flow 
cytometry. Cells positive for both CD11c and 7-AAD were considered to be DCs that had 
phagocytosed apoptotic cells. (B) The cross-presenting capacity of DCs. Immature 3d-DCs from a 
HLA-A*2402-positive donor were pulsed with apoptotic HLA-A*2402-negative donor-derived LCLs, 
matured with OK-432 and prostaglandin E2, and co-cultured with autologous T cells. For a positive 
control, DCs pulsed with the EBNA3B peptide were used as a stimulator. After 7 days, expansions of 
EBNA3A- and EBNA3B-specific CD8+ T cells were evaluated by HLA tetramer staining. Dead cells 
are excluded by staining with propidium iodide. Numbers shown indicate percentages of 
tetramer-positive cells among CD8+ cells. Representative data from two experiments are shown. 
 
Figure 2 Short-term stimulation with OK-432 is optimal to generate Th1-inducing mature DCs. (A, B) 
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Immature 3d-DCs were cultured in the presence of OK-432 (0.1 KE/mL) for indicated time periods, 
then harvested and analyzed. (C, D) Immature 3d-DCs were cultured in the presence of OK-432 for 
indicated time periods, washed, re-plated and further cultured for a total of 48 hours. Cells and 
supernatants harvested at 48 hours were analyzed. (A, C) Expression of CD83 and CD86 was analyzed 
by flow cytometry. Dead cells were excluded by staining with propidium iodide. Open histograms 
indicate staining with isotype controls. (B, D) IL-12p70 production in culture supernatants of DCs (5 x 
105 cells/mL) were measured by ELISA. Error bars indicate the standard deviation of duplicate 
measurements. (E) Naive CD4+ T cell differentiation induced by DCs. Immature 3d-DCs were matured 
with OK-432 (0.1 KE/mL) for 6 or 24 hours and co-cultured with allogeneic naive CD4+ T cells for 7 
days. Cytokine profiles of T cells were analyzed by intracellular cytokine staining. Numbers indicate 
percentages of cells in each quadrant. Representative data from four experiments are shown. 
 
Figure 3 IFN-γ ELISPOT assay in Patient #2. MNCs from peripheral blood (PB) and bone marrow 
(BM) were obtained at indicated time points, and subjected to IFN-γ ELISPOT assays directly after 
isolation (A) or after 1 week of stimulation with antigen-pulsed DCs (B). In IFN-γ ELISPOT assays, 2 
x 105 MNCs (A) and 1 x 104 MNCs (B) were incubated with 1 x 104 leukemic cell-pulsed or unpulsed 
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DCs. Numbers of specific spot-forming cells per 2 x 105 MNCs, calculated by subtracting numbers of 
spots with unpulsed DCs from numbers of spots with leukemic cell-pulsed DCs. Error bars indicate the 
standard deviation of duplicate measurements. 
 
Figure 4 Immune responses in Patient #3. (A) HLA tetramer staining. MNCs from peripheral blood 
were obtained at indicated time points, stimulated for 1 week with DCs pulsed with the modified 
WT1235-243 peptide, stained with PE-labeled peptide/HLA-A*2402 tetramers and FITC-labeled 
anti-CD8 mAb, and analyzed by flow cytometry. Dead cells were excluded by staining with propidium 
iodide. Numbers indicate percentages of tetramer-positive cells among CD8+ cells. (B) IFN-γ 
ELISPOT assay. MNCs were stimulated for 1 week with DCs pulsed with the hTERT461-469 or 
CMVpp65328-336 peptide, and subjected to IFN-γ ELISPOT assays. In the assays, 2 x 10
4 MNCs were 
incubated with 2 x 104 C1R-A*2402 pulsed with or without the hTERT461-469 or CMVpp65328-336 
peptide. Before vaccination, the assay was performed using DCs as a stimulator, which induced many 
non-specific spots. Thus, the data before vaccination are not shown. Numbers of specific spot-forming 
cells per 2 x 105 MNCs, calculated by subtracting numbers of spots with unpulsed C1R-A*2402 from 
numbers of spots with antigen-pulsed C1R-A*2402, were depicted. Error bars indicate the standard 
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deviation of duplicate measurements. 
 
Figure 5 Clinical courses during the DC vaccination. (A) Percentages of leukemic cells in bone 
marrow as determined by flow cytometry in 4 vaccinated patients are shown. Solid lines indicate 
patients with immune responses to leukemic cells (LCs) [Patients #2 (■) and #3 (▲)]. Dashed lines 
indicate patients without immune responses to LCs [Patients #1 (●) and #4 (♦)].Arrows indicate time 
points when DC vaccines were administered to each patient. (B) The clinical course of Patient #3. 
Arrows indicate time points when immunological monitoring was performed. Plus (+) or minus (-) 
signs indicates that immune responses to leukemic cells were detected or not detected at that time point, 
respectively. 
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Table 1 Patient characteristics and results of the DC vaccination 
Patient Age/Sex Diagnosis 
DC vac was started at LC in BM at 
the 1st vac * Adverse effects** 
Immune response 
Clinical response 
Died at (after 
the last vac) after the last CT after diagnosis KLH LC 
#1 76/F AML 
-MRC 
82 days 93 days 1.8% Fever (1) 
Injection site reaction (2) 
Yes No PD 
Died of sepsis with leukemia 
186 days 
#2 75/M AML 
-MRC 
40 days 155 days 0.6% Fever (1) 
Injection site reaction (2) 
Yes Yes Transient disease stabilization 
Died of leukemia 
391 days 
#3 70/M AML 
-MRC 
44 days 344 days 2.9% Fever (2) 
Injection site reaction (2) 
Yes Yes Transient disease stabilization 
Died of sepsis with leukemia 
192 days 
#4 66/M AML M2 67 days 144 days 0.2% Fever (1) 
Injection site reaction (2) 
No No PD 
Died of leukemia 
66 days 
Vac: vaccination, CT: chemotherapy, LC: leukemic cells, BM: bone marrow, AML-MRC: Acute myeloid leukemia with myelodysplasia-related changes, PD: Progressive disease 
*Percentages of leukemic cells in bone marrow were determined by flow cytometry. **Numbers in parenthesis indicate grade of toxicity according to the National Cancer Institute-Common 
Terminology Criteria for Adverse Events version 3.0. 
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Supplementary figure legends 
 
Supplementary Figure 1 3d-DCs and 6d-DCs have comparable T cell-stimulatory capacity. (A) 
Expressions of surface molecules on DCs. Unstimulated or OK-432-stimulated DCs were 
analyzed by flow cytometry. Dead cells were excluded by staining with propidium iodide. Open 
histograms indicate staining with isotype controls. (B) IL-12p70 production by DCs (5 x 10
5
 
cells/mL) stimulated with OK-432 (0.1 KE/mL) for 24 hours was measured by enzyme-linked 
immunosorbent assay (ELISA). Error bars indicate the standard deviation of duplicate 
measurements. (C) Proliferation of naive CD4
+
 T cells stimulated with DCs. Allogeneic naive 
CD4
+
 T cells were co-cultured with DCs at indicated DC:T cell ratios. On day 4, 1 μCi of 
[
3
H]-thymidine was added. After 16 hours of further incubation, thymidine uptake was counted. 
Naive CD4
+
 T cells were stimulated with 10 g/mL PHA as a positive control. Representative 
data from three experiments are shown. 
 
Supplementary Figure 2 Effects of cryopreservation on immature 3d-DCs. (A) Viability of fresh 
and frozen 3d-DCs after 24 hours of incubation with or without OK-432 (0.1 KE/mL) were 
 2 
evaluated by staining with Annexin V. Percentages of Annexin V-positive cells are indicated. (B) 
Expression of surface molecules on fresh and frozen DCs after 24 hours of incubation with or 
without OK-432. (C) IL-12p70 production by fresh and frozen DCs (5 x 10
5
 cells/mL) induced by 
24-hour stimulation with OK-432 was measured by ELISA. Error bars indicate the standard 
deviation of duplicate measurements. Representative data from four experiments are shown. 
 
Supplementary Figure 3 Expression of surface molecules on DCs for vaccination. 
Cryopreserved DCs from patients were thawed, stained, and analyzed by flow cytometry. Dead 
cells were excluded by staining with 7-AAD. Numbers indicate percentages of cells in each 




















































































































Supplementary Table 1  DC vaccine generation 
  At the time of apheresis  Antigen 
dose 
LC:DC Patient  
Days after 







#1  74 4700/μl 7% 0.9%    1:5 
#2  31 3000/μl 9% 2.0%    1:6.5 
#3  43 3900/μl 15% 0%**    1:6 
#4  46 4800/μl 16% 0.3%    1:3.3 
CT: chemotherapy, Mo: monocytes, LC: leukemic cells 
*Percentages of leukemic cells in bone marrow were determined by flow cytometry. **Patient #3 was in complete remission at the 
time of apheresis. The patient subsequently relapsed and became eligible for DC vaccination. 
 
